Prescribing biosimilars Slow adoption is costly

被引：9

作者：

Aronson, Jeffrey K. ^{[1
,2
]}

Goldacre, Ben ^{[1
]}

Ferner, Robin E. ^{[2
,3
]}

机构：

[1] Nuffield Dept Primary Care Hlth Sci, Ctr Evidence Based Med, Oxford, England

[2] City Hosp, West Midlands Ctr Adverse Drug React, Birmingham, W Midlands, England

[3] Univ Birmingham, Inst Clin Sci, Birmingham, W Midlands, England

来源：

BMJ-BRITISH MEDICAL JOURNAL | 2018年 / 362卷

关键词：

D O I：

10.1136/bmj.k3141

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 20 条

[1]

Aladul MI, 2018, RES SOC ADMIN PHARM, VS1551-7411, P30978, DOI [10.1016/j.sapharm.2018.05.009.29807834, DOI 10.1016/J.SAPHARM.2018.05.009.29807834]

[2] Biosimilar uptake by British local formularies: a cross sectional study [J].

Alnahar, Saja ;

Elliott, Rachel A. ;

Smith, Murray D. .

INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2017, 39 (05) :1055-1060

[3]

[Anonymous], 2013, EMACHMP5893172013

[4]

[Anonymous], 2004, COMP BIOT BIOL PROD

[5]

[Anonymous], 2016, FINANCIAL TIMES

[6] How similar are biosimilars? [J].

Aronson, Jeffrey K. ;

Ferner, Robin E. .

BMJ-BRITISH MEDICAL JOURNAL, 2016, 353

[7]

British National Formulary, NHS IND PRIC

[8] Biosimilar epoetins: An analysis based on recently implemented European medicines - Evaluation Agency guidelines on comparability of biopharmaceutical proteins [J].

Combe, C ;

Tredree, RL ;

Schellekens, H .

PHARMACOTHERAPY, 2005, 25 (07) :954-962

[9]

European Medicines Agency, 2014, CHMP43704REV1 EUR ME

[10]

European Medicines Agency, BIOS MED

← 1 2 →